Detailansicht

Wissensnetz

Person

Katerina Machova Polakova

Wissenschaftlerin

Name	Katerina Machova Polakova
Zeit	2023- (Wirkungsdaten)
Ort	Tschechische Republik
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Dr.
Beruf	Wissenschaftlerin (charakteristischer Beruf)
Variante	K. Machova Polakova Katerina Polakova K. Polakova
Beziehung	Institute of Hematology and Blood Transfusion (Prag) Univerzita Karlova
Weitere Angaben	Senior Researcher am Institute of Haematology and Blood Transfusion und Associate Professor an der Univerzita Karlova in Prag
Datensatztyp	Person
GND-Nummer	131911458X
Datensatz-ID	131911458X
Beteiligt an alle anzeigen Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Katerina Machova Polakova

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients

Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia